Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review
Children · 23.02.2023 · 10 (3) · 434
DOI: 10.3390/children10030434 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Children, online erschienen am 23.02.2023. Verfasst von Claudia Iannone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Juvenile idiopathic arthritis (JIA) associated uveitis (JIA-U) is the most common extra-articular manifestation of JIA, affecting 10–15% of patients, especially in oligoarticular JIA where its course may be faint. Therefore, JIA-U is one of the most challenging pediatric uveitis, associated with major ocular morbidity and possibly leading to irreversible structural ocular damage and to vision-threatening complications. Adequate management is crucial for avoiding visual impairment complications. Since the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDS), the visual prognosis of JIA-U has dramatically improved over the decades. Tumor necrosis factor-α (TNF-α) blockers are the most used bDMARDs in treating JIA-U with large evidence of efficacy. However, inadequate response to these agents, either due to intolerance or inefficacy, may be observed, requiring a swap to other classes of immunosuppressive agents, including anti-IL-6, anti-CD20, and, more recently, JAK inhibitors. Tocilizumab is a humanized monoclonal antibody to the interelukin-6 receptor preventing IL-6 from binding to its soluble and membrane-bound receptors. A growing body of literature provides promising results about the efficacy of intravenous and subcutaneous tocilizumab in the treatment of JIA-U. A narrative review of the literature on this topic will improve our knowledge on the potential use of tocilizumab in JIA-U.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, 20122 Milan, Italy.
- Faculty of Medicine, University of Milan, 20122 Milan, Italy.
- Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, 20122 Milan, Italy.
- Ophthalmology Department, Ospedale San Raffaele, University Vita-Salute, 20132 Milan, Italy.
ORCID-Profile: Claudia Iannone
Zitieren
APA
Iannone, C., Marelli, L., Costi, S., Pellico, M. R., La Franca, L., Caporali, R., & Miserocchi, E. (2023). Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review. Children, 10(3), 434. https://doi.org/10.3390/children10030434
Vancouver
Iannone C, Marelli L, Costi S, Pellico MR, La Franca L, Caporali R, et al. Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review. Children. 2023;10(3):434. doi:10.3390/children10030434
BibTeX
@article{Iannone2023,
author = {Iannone, Claudia and Marelli, Luca and Costi, Stefania and Pellico, Maria Rosa and La Franca, Lamberto and Caporali, Roberto and Miserocchi, Elisabetta},
title = {Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis, a Narrative Review},
journal = {Children},
year = {2023},
volume = {10},
number = {3},
pages = {434},
doi = {10.3390/children10030434}
}
EUVIMED